The clinical trial, which began in March, first investigated various reduced dosages of the Pfzier-BioNTech Covid-19 vaccine in children ages 5 to 11. “Parents were given a diary to report symptoms on a daily basis for seven days after children received each dose of vaccine,” Walter said. Levels of antibody protection in the younger children were then compared to levels seen in older children and adults up to age 30. Results showed children ages 5 to 11 produced similar levels of protection as the larger doses provided to older children and adults. If CDC Director Dr. Rochelle Walensky signs off on that recommendation, younger children could be getting vaccinated next week.

Source: CNN October 28, 2021 20:56 UTC